Drugs / BRL-301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07248163 | Mar 2025 → Aug 2027 expected | B-cell non-Hodgkin lymphoma | Bioray Laboratories | Recruiting | No outcome recorded |
| — | NCT05988216 | Aug 2023 → Dec 2024 overdue | systemic lupus erythematosus | Bioray Laboratories | Recruiting | No outcome recorded |
| — | NCT05859997 | May 2023 → May 2024 overdue | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, myositis disease +2 | Bioray Laboratories | Enrolling by invitation | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRL-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07248163 ↗ |
| Action | Deplete | “achieving complete B cell depletion within 2 weeks of treatment” PMID 39013470 ↗ Jul 2024 |
| Modality | Cell therapy | “genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells” PMID 40446794 ↗ May 2025 |
| Route | Intravenous | “infused intravenously at a dose of 1 million cells per kilogram of body weight” PMID 40446794 ↗ May 2025 |
| Target | CD19 | “targeting CD19 Gene” NCT05988216 ↗ |